Page last updated: 2024-11-07

sarsasapogenin, (3beta,5alpha,25r)-isomer

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tigogenin : A widely used steroidal sapogenin isolated from several plant species and used for synthesizing steroid drugs. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID99516
CHEMBL ID43871
CHEBI ID9595
SCHEMBL ID330309
MeSH IDM0322426

Synonyms (43)

Synonym
77-60-1
5-alpha-spirostan-3-beta-ol
C08914
tigogenin
(25r)-5alpha-spirostan-3beta-ol
5-alpha-spirostan-3-beta-ol, (25r)-
spirostan-3-ol, (3beta,5alpha,25r)-
einecs 201-041-9
(5alpha,25r)-spirostan-3beta-ol
brn 1293741
(3-beta,5-alpha,25r)-spirostan-3-ol
nsc 93754
5alpha-spirostan-3beta-ol, (25r)-
5,6-dihydrodiosgenin
chebi:9595 ,
CHEMBL43871
(25r)-5a-spirostan-3b-ol
LMST01080009
unii-4smu15rr44
4smu15rr44 ,
spirostan-3-ol, (3b,5a,25r)-
AKOS016002078
tigogenin [mi]
ticogenin
SCHEMBL330309
GMBQZIIUCVWOCD-MFRNJXNGSA-N
(3-beta,5alpha,25r)-spirostan-3-ol
5-epi-sarsasapogenin
Q-201833
(2as,2'r,4s,5'r,6as,6bs,8as,8br,9s,11as,12as,12br)-5',6a,8a,9-tetramethyldocosahydrospiro[naphtho[2',1':4,5]indeno[2,1-b]furan-10,2'-pyran]-4-ol
(3beta,5alpha,25r)-spirostan-3-ol
(1'r,2r,2's,4's,5r,7's,8'r,9's,12's,13's,16's,18's)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0?,?.0?,?.0??,??]icosane]-16'-ol
mfcd00067287
HY-N1403
BS-18122
Q27108442
(1r,2s,4s,5'r,6r,7s,8r,9s,12s,13s,16s,18s)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-16-ol
CS-0016821
DTXSID40903920
S5334
22-isoallospirostan-3|a-ol
tigogenin 90%; (25r)-5-alpha-spirostan-3-beta-ol
A865190
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
gout suppressantA drug that increases uric acid excretion by the kidney (uricosuric drug), decreases uric acid production (antihyperuricemic), or alleviates the pain and inflammation of acute attacks of gout.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
sapogeninAny organic polycyclic compound that is the aglycon moiety of a saponin; sapogenins may be steroids or triterpenoids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
UDP-glucuronosyltransferase 1A4Homo sapiens (human)Km7.00007.00007.00007.0000AID214939
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
bilirubin conjugationUDP-glucuronosyltransferase 1A4Homo sapiens (human)
heme catabolic processUDP-glucuronosyltransferase 1A4Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A4Homo sapiens (human)
vitamin D3 metabolic processUDP-glucuronosyltransferase 1A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
retinoic acid bindingUDP-glucuronosyltransferase 1A4Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A4Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
endoplasmic reticulumUDP-glucuronosyltransferase 1A4Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A4Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID594712Antifungal activity against Candida glabrata ATCC 48435 after 48 hrs by broth microdilution method2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Synthesis and antifungal activity of functionalized 2,3-spirostane isomers.
AID594709Antifungal activity against Cryptococcus neoformans ATCC 36556 assessed as reduction in growth after 48 hrs by broth microdilution method relative to control2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Synthesis and antifungal activity of functionalized 2,3-spirostane isomers.
AID624607Specific activity of expressed human recombinant UGT1A32000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID594707Antifungal activity against Candida albicans ATCC 10231 assessed as reduction in growth after 48 hrs by broth microdilution method relative to control2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Synthesis and antifungal activity of functionalized 2,3-spirostane isomers.
AID214939Binding affinity against human UDP Glucuronosyltransferase 1A4 (UGT1A4)2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Pharmacophore and quantitative structure-activity relationship modeling: complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID629787Inhibition of human NF-kappaB in HEK cells by luciferase reporter gene assay2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Microbial transformations of diosgenin by the white-rot basidiomycete Coriolus versicolor.
AID594710Antifungal activity against Aspergillus fumigatus ATCC 16424 after 48 hrs by broth microdilution method2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Synthesis and antifungal activity of functionalized 2,3-spirostane isomers.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.13 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (33.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]